Opiant Pharmaceuticals, Inc. (OPNT)
Stock Price:
$9.19 USD
0.00 (0.00%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
39.13M |
| Revenue (ttm) |
38.90M |
| Net Income (ttm) |
9.85M |
| Shares Out |
4.26M |
| EPS (ttm) |
1.89 |
| PE Ratio |
4.86 |
| Forward PE |
26.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$9.19 |
| Previous Close |
$9.19 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
9.24 |
| Day's Range |
8.85 - 9.24 |
| Day's Volume |
32,748 |
| 52-Week Range |
8.05 - 18.23 |
More Stats
| Market Cap |
39.13M |
| Enterprise Value |
9.14M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.26M |
| Float |
3.06M |
| EPS (basic) |
2.43 |
| EPS (diluted) |
1.89 |
| FCF / Share |
1.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
20.57% |
| FCF Yield |
12.84% |
| Payout Ratio |
n/a |
| Shares Short |
11,069 |
| Short Ratio |
0.16 |
| Short % of Float |
0.23% |
| Beta |
0.58 |
| PE Ratio |
4.86 |
| Forward PE |
26.74 |
| P/FCF Ratio |
7.79 |
| PS Ratio |
1.01 |
| PB Ratio |
1.15 |
| Revenue |
38.90M |
| Operating Income |
9.38M |
| Net Income |
9.85M |
| Free Cash Flow |
5.03M |
| Net Cash |
29.99M |
| Net Cash / Share |
7.04 |
| Gross Margin |
60.97% |
| Operating Margin |
24.10% |
| Profit Margin |
25.30% |
| FCF Margin |
12.92% |
| ROA |
17.17% |
| ROE |
36.24% |
| ROIC |
188.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$40.00*
(335.26% upside)
Low
38.0
Current: $9.19
High
42.0
Target: 40.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 40.52 | 13.98 | 18.45 | 9.90 | 1.55 | - | - | - | - | - |
| Revenue Growth | 189.8% | -24.2% | 86.37% | 538.55% | - | - | - | - | - | - |
| Gross Profit | 40.52 | 13.98 | 18.45 | 9.90 | 1.55 | - | - | - | - | - |
| Operating Income | 10.91 | -21.19 | 7.09 | -7.74 | -6.90 | -11.30 | -8.81 | -12.34 | -9.44 | -2.02 |
| Net Income | 11.59 | -21.20 | 6.58 | -7.81 | -7.04 | -11.48 | -9.18 | -12.42 | -9.44 | -2.02 |
| Shares Outstanding | 4.02 | 2.99 | 2.01 | 1.91 | 1.81 | 1.75 | 1.43 | 1.04 | 0.67 | 0.87 |
| Earnings Per Share | 2.17 | -7.10 | 2.94 | -4.09 | -3.88 | -6.57 | -6.00 | -12.00 | -14.00 | -2.00 |
| Operating Cash Flow | 4.06 | -0.52 | 5.56 | -0.92 | -4.24 | -1.01 | -0.75 | -1.10 | -2.96 | -0.38 |
| Capital Expenditures | -0.30 | - | - | -0.01 | - | - | - | - | - | - |
| Free Cash Flow | 3.76 | -0.52 | 5.56 | -0.92 | -4.24 | -1.01 | -0.75 | -1.10 | -2.96 | -0.38 |
| Cash & Equivalents | 30.98 | 24.61 | 6.87 | 1.48 | 0.43 | 0.25 | 0.60 | 0.02 | 0.05 | 0.00 |
| Total Debt | 0.77 | - | - | 0.17 | - | - | 0.03 | 0.22 | - | - |
| Net Cash / Debt | 30.21 | 24.61 | 6.87 | 1.32 | 0.43 | 0.25 | 0.57 | -0.20 | 0.05 | 0.00 |
| Assets | 40.28 | 29.39 | 10.81 | 1.88 | 0.49 | 0.30 | 0.64 | 0.04 | 0.08 | 0.02 |
| Liabilities | 5.86 | 12.53 | 6.47 | 6.59 | 8.87 | 3.38 | 1.63 | 0.66 | 0.42 | 0.66 |
| Book Value | 34.42 | 16.86 | 4.33 | -4.70 | -8.39 | -3.08 | -0.99 | -0.62 | -0.34 | -0.64 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Opiant Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
21 |
| CEO |
Roger Crystal |
Stock Information
| Ticker Symbol |
OPNT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OPNT |
Description
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.